Histamine H4 receptor is a potential target for COVID-19 treatment

Details
Parent Category: Year 2020, Volume 12
Category: Volume 12, Issue 4, October-December 2020
Hits: 1623
Abstract
Pulmonary fibrosis and cytokine storms are two major complications in COVID-19 patients that can decrease life quality after recovery and even cause death. Histamine H4 Receptor (H4R) antagonists prevent lung fibrosis and reduce TNF-α and IL-6 secretion in several immune-mediated diseases. T-helper cell 17 (TH17), which is an important inflammatory effector in COVID-19 pathogenesis, expresses H4Rs on its surface. The stimulation of these receptors results in IL-17 production and, subsequently, TNF-α and IL-6 secretion, tissue remodelling, and fibrosis. The compatibility of the clinical manifestations of COVID-19 with the H4R function pattern further supports this theory. According to the above content, Histamine 4 receptors could be a potential target for COVID-19 treatment. H4R antagonists should be evaluated in experimental in-vitro studies and randomized controlled trials in terms of their therapeutic and preventive effects in COVID-19 complications, severity progression, and mortality.
 
Keywords: COVID-19, Histamine, H4R, Histamine H4 receptor

 

» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7776

The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.

 

To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here

 

Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.

 

The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:

 

TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: